Program
Budesonide
Also written as “budesonide”, “budesonide/formoterol” and “BGF MDI 320/14.4/9.6 μg”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Eosinophilic Esophagitis · Colitis, Ulcerative · Glomerulonephritis, IGA, led by 35 companies.
Drug pageBudesonide: every studyMany companies study it; this page follows only the 163 they lead. All 307 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 692 open or running | phase 4since Sep 27, 2005 | Sep 13, 2005 | May 31, 2027phase 4 · NCT07073950 |
| Dr. Falk Pharmaits history only | 171 open or running | phase 3since Mar 7, 2006 | Mar 7, 2006 | Dec 2026phase 3 · NCT06596252 |
| Bausch Health Companiesits history only | 91 open or running | phase 4since Mar 17, 2020 | May 14, 2008 | Dec 2026phase 4 · NCT04314375 |
| Takedaits history only | 60 open or running | phase 3since Nov 4, 2015 | Sep 29, 2008 | none ahead |
| AbbVieits history only | 50 open or running | phase 3since Dec 5, 2007 | Oct 30, 2007 | none ahead |
| Calliditas Therapeutics ABits history only | 51 open or running | phase 4since Nov 20, 2024 | Oct 5, 2008 | Mar 2027phase 4 · NCT06712407 |
| Intech Biopharmits history only | 50 open or running | phase 2since Jun 11, 2014 | Jun 11, 2014 | none ahead |
| Chenpon Pharmaceuticalits history only | 30 open or running | phase 3since Aug 24, 2026 | Aug 24, 2026 | none ahead |
| Eurofarma Laboratoriosits history only | 30 open or running | phase 3since Oct 23, 2009 | Oct 23, 2009 | none ahead |
| Novartisits history only | 30 open or running | phase 4since Feb 15, 2013 | Feb 15, 2013 | none ahead |
| Orion Corporation, Orion Pharmaits history only | 30 open or running | phase 2since Aug 24, 2009 | Aug 24, 2009 | none ahead |
| Padagisits history only | 30 open or running | phase 3since Sep 28, 2011 | Sep 28, 2011 | none ahead |
| Aquilon Pharmaceuticalsits history only | 20 open or running | phase 2since May 31, 2021 | May 31, 2021 | none ahead |
| Bond Avillion 2 Development LPits history only | 20 open or running | phase 3since Nov 30, 2018 | Nov 30, 2018 | none ahead |
| Ferring Pharmaceuticalsits history only | 20 open or running | phase 3since Jan 22, 2018 | Jan 22, 2018 | none ahead |
| Ligand Pharmaceuticalsits history only | 20 open or running | phase 2since Jul 13, 2009 | Jul 13, 2009 | none ahead |
| Pari Pharmaits history only | 20 open or running | phase 2since Sep 4, 2013 | Sep 4, 2013 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 3since Feb 12, 2014 | Feb 12, 2014 | none ahead |
| Triastek, lnc.its history only | 22 open or running | phase 1since Oct 13, 2026 | Oct 13, 2026 | Dec 2026phase 1 · NCT07897240 |
| Vecturaits history only | 20 open or running | phase 1since Jan 12, 2018 | Jan 12, 2018 | none ahead |
| Zambon SpAits history only | 20 open or running | phase 1since Sep 2, 2014 | Sep 2, 2014 | none ahead |
| Abbottits history only | 10 open or running | phase 1since Jul 26, 2022 | Jul 26, 2022 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 10 open or running | phase 3since Jul 25, 2016 | Jul 25, 2016 | none ahead |
| Activaeroits history only | 10 open or running | phase 2since Sep 10, 2010 | Sep 10, 2010 | none ahead |
| Bazell Pharmaits history only | 10 open or running | phase 2since Jan 3, 2022 | Jan 3, 2022 | none ahead |
| Chiesi Farmaceuticiits history only | 10 open or running | phase 3since May 18, 2007 | May 18, 2007 | none ahead |
| Ciplaits history only | 10 open or running | phase 3since Mar 31, 2022 | Mar 31, 2022 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Apr 18, 2021 | Apr 18, 2021 | none ahead |
| Hamad Medicalits history only | 11 open or running | phase 3since May 25, 2015 | May 25, 2015 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 4since Oct 17, 2019 | Oct 17, 2019 | none ahead |
| Kindeva Drug Deliveryits history only | 10 open or running | phase 3since Jan 6, 2017 | Jan 6, 2017 | none ahead |
| Lunan Pharmaceutical Groupits history only | 10 open or running | no phasesince Mar 29, 2025 | Mar 29, 2025 | none ahead |
| Marinomed Biotechits history only | 10 open or running | phase 3since Nov 21, 2018 | Nov 21, 2018 | none ahead |
| Rafa Laboratoriesits history only | 10 open or running | phase 3since Aug 9, 2005 | Aug 9, 2005 | none ahead |
| Unither Pharmaceuticals, Franceits history only | 10 open or running | phase 1since Sep 6, 2024 | Sep 6, 2024 | none ahead |
Also a collaborator on its studies: Parexel, Fortrea, Takeda Development Center Americas, Iqvia Pty, Premier, Hikma Pharmaceuticals, Cosmo Technologies, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan, Q-Pharm Pty and Kyowa Kirin.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Nov 11, 2005.
- Feb 17, 2016Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT03262012 · 416 enrolled · Japan
- May 6, 2016Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT02766608 · 2,389 enrolled · United States, Canada, Czechia and more
- Sep 24, 2018Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT03836677 · 23 enrolled · Belgium, Netherlands
- Oct 26, 20202 phase 3 studies in AsthmaNCT04609904, NCT04609878
- Jan 10, 2022Phase 3 study in AsthmaNCT05202262 · 645 enrolled · United States, Canada, Germany and more
- Feb 23, 2023Phase 3 study in AsthmaNCT05755906 · 374 enrolled · United States, Canada, Czechia and more
- Jun 27, 2023Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT05970263
- Sep 28, 2023Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06067828 · 171 enrolled · United States, Canada, China and more
- Dec 13, 2023Phase 3 study in Asthma, Exercise-InducedNCT06245551 · 64 enrolled · Russia
- Feb 21, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06283966 · 5,250 planned · United States, Argentina, Australia and more
- May 29, 2024Phase 1 study in Healthy VolunteerNCT06514157 · 14 enrolled · China
- Aug 19, 2024Phase 4 study in Respiratory HypersensitivityNCT06563102 · 101 enrolled · United States
- Jul 17, 2025Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT07073950 · 56 planned · Germany, United Kingdom
- Feb 20, 2026Phase 1 study in AsthmaNCT07433569 · 16 enrolled · United States
Ahead
- May 31, 2027Primary completion: phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT07073950
- Dec 3, 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06283966
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
The newest 60 of 69 AstraZeneca leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07433569Asthma · United States | 1 | Completed | Jun 26, 2026 | 16 |
| NCT07073950Pulmonary Disease, Chronic Obstructive · Germany, United Kingdom | 4 | Recruiting | May 31, 2027 | 56 |
| NCT06563102Respiratory Hypersensitivity · United States | 4 | Completed | Feb 24, 2026 | 101 |
| NCT06514157Healthy Volunteer · China | 1 | Completed | Sep 9, 2024 | 14 |
| NCT06283966Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Recruiting | Dec 3, 2027 | 5,250 |
| NCT06245551Asthma, Exercise-Induced · Russia | 3 | Completed | Jun 29, 2024 | 64 |
| NCT06067828Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more | 3 | Completed | Jan 22, 2026 | 171 |
| NCT05970263Pulmonary Disease, Chronic Obstructive | 4 | Withdrawn | Dec 31, 2025 | 0 |
| NCT05755906Asthma · United States, Canada, Czechia and more | 3 | Completed | Nov 19, 2024 | 374 |
| NCT05202262Asthma · United States, Canada, Germany and more | 3 | Completed | Feb 26, 2025 | 645 |
| NCT04609904Asthma · United States, Brazil, China and more | 3 | Completed | Mar 20, 2025 | 2,187 |
| NCT04609878Asthma · United States, Argentina, Belgium and more | 3 | Completed | Mar 21, 2025 | 2,274 |
| NCT03836677Pulmonary Disease, Chronic Obstructive · Belgium, Netherlands | 3 | Completed | Nov 11, 2019 | 23 |
| NCT02766608Pulmonary Disease, Chronic Obstructive · United States, Canada, Czechia and more | 3 | Completed | Dec 1, 2017 | 2,389 |
| NCT03262012Pulmonary Disease, Chronic Obstructive · Japan | 3 | Completed | Jun 15, 2018 | 416 |
| NCT02536508Pulmonary Disease, Chronic Obstructive · United States | 3 | Completed | Sep 12, 2017 | 627 |
| NCT02533505Pulmonary Disease, Chronic Obstructive · United States | 4 | Completed | Aug 12, 2016 | 51 |
| NCT02497001Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more | 3 | Completed | Jan 5, 2018 | 1,902 |
| NCT02465567Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Completed | Jul 26, 2019 | 8,588 |
| NCT02196077Pulmonary Disease, Chronic Obstructive · United States | 2 | Completed | Mar 1, 2015 | 180 |
| NCT02189304Pulmonary Disease, Chronic Obstructive · United States | 1 | Completed | Sep 1, 2014 | 59 |
| NCT01360021Asthma · United States, Bulgaria, Hungary and more | 3 | Completed | Aug 2012 | 214 |
| NCT01257048Pulmonary Disease, Chronic Obstructive · Sweden, United Kingdom | Early 1 | Completed | Jun 2012 | 34 |
| NCT01136382Asthma · United States, Bulgaria, Hungary and more | 2 | Completed | Apr 2013 | 304 |
| NCT00989833Asthma, Exercise-Induced · Norway, Sweden | 2 | Completed | Jul 2010 | 66 |
| NCT00855959Asthma · Japan | 3 | Completed | Aug 2009 | 108 |
| NCT00658255Stable Asthma | 2 | Completed | 175 | |
| NCT00652392Asthma | 3 | Completed | 750 | |
| NCT00652002Asthma | 3 | Completed | 450 | |
| NCT00651768Asthma | 3 | Completed | 570 | |
| NCT00651651Asthma | 3 | Completed | 450 | |
| NCT00651547Asthma | 3 | Completed | 405 | |
| NCT00646009Asthma | 3 | Completed | 48 | |
| NCT00642187Asthma | 3 | Completed | Oct 2004 | 525 |
| NCT00642161Asthma | 3 | Completed | Sep 2004 | 430 |
| NCT00642122Asthma | 3 | Completed | Dec 2004 | 900 |
| NCT00641979Rhinitis, Allergic, Seasonal | 2 | Completed | Aug 2002 | 200 |
| NCT00641914Asthma | 4 | Completed | Feb 2003 | 6,800 |
| NCT00641693Rhinitis, Allergic | 2 | Completed | May 2005 | 650 |
| NCT00641680Rhinitis, Allergic, Seasonal | 3 | Completed | Jul 2003 | 750 |
| NCT00641472Asthma | 4 | Completed | Feb 2005 | 380 |
| NCT00641446Asthma | 4 | Completed | Oct 2003 | 250 |
| NCT00641212Rhinitis, Allergic, Perennial | 4 | Completed | Apr 2003 | 209 |
| NCT00536731Asthma · Bulgaria, Czech Republic, Hungary and more | 3 | Completed | Apr 2008 | 742 |
| NCT00536913Asthma · Hungary, Poland, Russian Federation | 3 | Completed | Feb 2008 | 107 |
| NCT00509028Asthma · Japan | 3 | Completed | Oct 2008 | 241 |
| NCT00504062Asthma · Japan | 3 | Completed | 240 | |
| NCT00489853Pulmonary Disease, Chronic Obstructive · Germany, Switzerland | 4 | Completed | Aug 2008 | 137 |
| NCT00463866Asthma · Belgium, Finland, France and more | 4 | Completed | 8,424 | |
| NCT00421122Pulmonary Disease, Chronic Obstructive · China | 3 | Completed | 315 | |
| NCT00326053Asthma · Canada | 3 | Completed | 600 | |
| NCT00319306Asthma · United Kingdom | 3 | Completed | 550 | |
| NCT00290264Asthma · Belgium, Luxembourg | 3 | Completed | 1,000 | |
| NCT00288379Asthma · Sweden | 3 | Completed | 16 | |
| NCT00272753Asthma · Netherlands | 4 | Completed | 20 | |
| NCT00259792Asthma · France | 3 | Completed | 1,000 | |
| NCT00259779Pulmonary Disease, Chronic Obstructive · Denmark, Finland, Germany and more | 3 | Completed | 120 | |
| NCT00259766Asthma · Sweden | 3 | Completed | 1,970 | |
| NCT00255255Asthma · Japan | 3 | Completed | Dec 2006 | 120 |
| NCT00252785Asthma · Japan | 3 | Completed | 340 |
How it is read
Names in the registry
- “Budesonide”, 45 entries
- “budesonide”, 18 entries
- “budesonide/formoterol”, 10 entries
- “BGF MDI 320/14.4/9.6 μg”, 6 entries
- “BFF MDI 320/9.6 μg”, 5 entries
Conditions, from the studies’ own filings
- Asthma, 75 studies
- Pulmonary Disease, Chronic Obstructive, 23 studies
- Eosinophilic Esophagitis, 10 studies
- Colitis, Ulcerative, 9 studies
- Glomerulonephritis, IGA, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.